Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial-Reference-Cited by-同舟云学术

Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial

Published:2019-07-15 Issue:14 Volume:8 Page:6195-6211
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zhu Feng‐Cai¹,Hu Shang‐Ying²,Hong Ying³,Hu Yue‐Mei¹,Zhang Xun²,Zhang Yi‐Ju¹,Pan Qin‐Jing²,Zhang Wen‐Hua²,Zhao Fang‐Hui²^ORCID,Zhang Cheng‐Fu⁴,Yang Xiaoping⁵,Yu Jia‐Xi⁶,Zhu Jiahong⁴,Zhu Yejiang⁷,Chen Feng²,Zhang Qian²,Wang Hong²,Wang Changrong⁵,Bi Jun⁶,Xue Shiyin⁴,Shen Lingling⁶,Zhang Yan‐Shu⁷,He Yunkun⁸,Tang Haiwen⁸,Karkada Naveen⁹,Suryakiran Pemmaraju⁹,Bi Dan¹⁰,Struyf Frank¹⁰

Affiliation:

1. Jiangsu Province Center for Disease Prevention and Control Nanjing China

2. National Cancer Center ‐ Cancer Hospital Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC) Beijing China

3. Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing China

4. Lianshui Center for Disease Prevention and Control Lianshui China

5. Jintan Center for Disease Prevention and Control Jintan China

6. Xuzhou Center for Disease Prevention and Control Xuzhou China

7. Binhai Center for Disease Prevention and Control Yancheng China

8. GSK Shanghai China

9. GSK Bangalore India

10. GSK Wavre Belgium

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2399

Reference44 articles.

1. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

2. Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis

3. Carcinogenicity of human papillomaviruses

4. Cancer statistics in China, 2015

5. ICO/IARC Information Centre on HPV and Cancer.China. Human papillomavirus and related cancers fact sheet 2016.http://www.hpvcentre.net/statistics/reports/CHN_FS.pdf. Accessed September 2016.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018–2020;Human Vaccines & Immunotherapeutics;2023-12

2. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis;Expert Review of Vaccines;2023-11-27

3. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China;Human Vaccines & Immunotherapeutics;2023-08

4. A feasibility assessment of real‐world data capabilities for monitoring vaccine safety and effectiveness in China: Human papillomavirus vaccination in the Yinzhou district as a use case;Pharmacoepidemiology and Drug Safety;2023-06-15

5. Knowledge and Attitudes towards Human Papillomavirus Vaccination (HPV) among Healthcare Providers Involved in the Governmental Free HPV Vaccination Program in Shenzhen, Southern China;Vaccines;2023-05-18